Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Hindustan Bio Sciences Ltd Stock Analysis

Small Cap
Evaluated by 129 users | BSE: 532041 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed -0.68%-7.05%-9.86%-16.69%-10.61%-8.5%-49.14%2.59%1.67%-23.21%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 2.73.92.30.81.3113.61.911
Y-o-Y Gr. Rt.-43.5%-42.2%-66.2%65.8%-19.8%2%245.6%-45.5%-46.9%-
Adjusted EPS (Rs.) -0.08-0.7-0.92-1.41-0.72-0.48-2.220.110.08-0.91-1.04
Y-o-Y Gr. Rt.-NANANANANANANA-27.3%-1237.5%-
Book Value per Share (Rs.) 9.328.848.046.744.74.2222.112.191.271.20
Adjusted Net Profit -0.1-0.7-1-1.5-0.7-0.5-2.30.10.1-0.9-1
Net Op. Cash Flow (Rs. Cr.) -0.30-0.5-0.30.5-0.2-0.2-1.30.80.8-
Debt to Cash Flow from Ops -0.434.18-1.69-3.552.07-8.03-6.86-2.553.162.47-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Hindustan Bio Sciences Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -10.2%-4%0-46.9%
Adjusted EPS NANANA-1237.5%
Book Value per Share -19.9-23-14.1-42
Share Price 6.8% 26% 64.7% 117%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) -0.85-7.34-10.6-18.87-12.65-10.74-71.35.273.67-52.63-84.21
Operating Profit Margin (%) -0.8-16.56-37.97-184.01-9.76-46-227.913.777-90.3-143.16
Net Profit Margin (%) -3.2-18.43-41.93-190.84-58.86-48.55-220.653.124.16-90.5-159.1
Debt to Equity 0.020.020.090.140.20.30.761.561.161.42-
Working Capital Days 9747071,1923,1331,6732,0691,6534591,0011,543-
Cash Conversion Cycle 48832013839311999105256132-
Loading price chart...
Entity Percentage Holding
Promoters 12.19%
Non-Institutions 87.81%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Hindustan Bio Sciences Ltd's earnings have grown by 0%, whereas share price has appreciated 26% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Hindustan Bio Sciences Ltd share price has appreciated 6.8% annually (CAGR) over the past ten years.

Data is not available for this company.

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.

The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).

Products

The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.

Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.

In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback